Background/Aims: The epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib is effective against several malignancies and is mainly utilized in the treatment of epidermal growth factor receptor mutation positive non-small cell lung cancer. The anti-cancer effect of the drug involves stimulation of apoptosis. Side effects of gefitinib include anemia. At least in theory, the development of anemia during gefitinib treatment could result from triggering of eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and by cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Signaling potentially stimulating eryptosis include increase of cytosolic Ca 2+ activity ([Ca 2+ ] i ) and generation of oxidative stress. The present study explored, whether gefitinib stimulates eryptosis and, if so, whether its effect involves Ca 2+ entry and/or oxidative stress. Methods: Flow cytometry was employed to quantify cell volume from forward scatter, phosphatidylserine exposure at the cell surface from annexin-V-binding, [Ca 2+ ] i from Fluo3-fluorescence, and reactive oxygen species (ROS) abundance from 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) dependent fluorescence. Results: A 48 hours exposure of human erythrocytes to gefitinib (≥ 2 µg/ml) significantly decreased forward scatter and significantly increased the percentage of annexin-V-binding cells. Gefitinib did not significantly increase Fluo3-fluorescence but the effect of gefitinib on annexin-V-binding was significantly blunted by removal of extracellular Ca 2+ . Gefitinib further significantly increased DCFDA fluorescence. Conclusions: Gefitinib triggers erythrocyte shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect at least in part dependent on extracellular Ca 2+ and paralleled by oxidative stress.
Introduction
The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib [1] is used for the treatment of non-small cell lung cancer carrying an epidermal growth factor receptor mutation . Gefitinib has further been shown to be effective in other malignancies [36] , such as other lung cancers [37] , breast cancer [38] , squamous cell carcinoma [36] , and colorectal cancer [36] . Moreover, gefitinib has been used in ectopic pregnancy [39] . Gefitinib is effective against malignancy at least in part by triggering suicidal death or apoptosis of tumor cells [40] [41] [42] [43] .
Side effects of gefitinib may include anemia [44] [45] [46] [47] [48] [49] . In theory, the anemia could result from suicidal death of erythrocytes or eryptosis [50] . Hallmarks of eryptosis are cell shrinkage [51] and breakdown of phosphatidylserine asymmetry of the cell membrane with phosphatidylserine translocation to the erythrocyte surface [50] . Signaling contributing to the orchestration of eryptosis include increase of cytosolic Ca 2+ activity ([Ca 2+ ] i ) [50] , ceramide [52] , caspases [50, 53, 54] , G-protein Galphai2 [55] , casein kinase 1α [50] , Janus-activated kinase JAK3 [50] , protein kinase C [50] , and p38 kinase [50] . Inhibitors of eryptosis include AMP activated kinase AMPK [50] , cGMP-dependent protein kinase [50] , mitogen and stress activated kinase MSK1/2 [56] , PAK2 kinase [50] and sorafenib/sunitinib sensitive kinases [50] . Eryptosis is stimulated by hyperosmotic shock [50] , oxidative stress [50] , energy depletion [50] , or a myriad of xenobiotics [50, . Augmented eryptosis is observed in several clinical conditions including iron deficiency [50] , dehydration [116] , hyperphosphatemia [117] , chronic kidney disease (CKD) [118] [119] [120] [121] , hemolytic-uremic syndrome [122] , diabetes [123] , hepatic failure [57] , malignancy [124, 125] , arteriitis [126] , sepsis [127] , sickle-cell disease [50] , beta-thalassemia [50] , Hb-C and G6PD-deficiency [50] , Wilsons disease [127] , as well as advanced age [128] . Eryptosis further increases during storage of blood for transfusion [129] .
The present study explored, whether gefitinib could trigger eryptosis, which would provide an explanation for gefitinib induced anemia. To this end, human erythrocytes from healthy volunteers were exposed to gefitinib and the hallmarks of eryptosis, phosphatidylserine surface abundance and cell volume determined by flow cytometry. In order to shed light on the underlying signaling [Ca 2+ ] i , and formation of reactive oxygen species (ROS) were determined by flow cytometry.
Materials and Methods

Erythrocytes, solutions and chemicals
Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). The blood was centrifuged at 120 g for 20 min at 21 °C and the platelets and leukocytes-containing supernatant was disposed. Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO 4 , 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES; pH 7.4), 5 glucose, 1 CaCl 2 , at 37°C for 48 hours. Where indicated, erythrocytes were exposed for 48 hours to gefitinib (Sigma Aldrich, Hamburg, Germany). In order to estimate the impact of Ca 2+ entry on gefitinib induced eryptosis, erythrocytes were exposed to gefitinib in the presence and absence of extracellular Ca
2+
.
Annexin-V-binding and forward scatter
After incubation under the respective experimental condition, a 150 µl cell suspension was washed in Ringer solution containing 5 mM CaCl 2 and then stained with Annexin-V-FITC (1:200 dilution; ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 15 min under protection from light. The annexin-Vabundance at the erythrocyte surface was subsequently determined on a FACS Calibur (BD, Heidelberg, Germany). Annexin-V-binding was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. A marker (M1) was placed to set an arbitrary threshold between annexin-V-binding cells and control cells. The same threshold was used for untreated and gefitinib treated erythrocytes. A dot plot of forward scatter (FSC) vs. side scatter (SSC) was set to linear scale for both parameters. The threshold of forward scatter was set at the default value of "52".
Intracellular Ca
2+
of 488 nm and an emission wavelength of 530 nm on a FACS Calibur. Afterwards, the geomean of the Ca 2+ dependent fluorescence was determined.
Reactive oxygen species (ROS)
Oxidative stress was determined utilizing 2',7'-dichlorodihydrofluorescein diacetate (DCFDA). After incubation, a 150 µl suspension of erythrocytes was washed in Ringer solution and stained with DCFDA (Sigma, Aldrich, Germany) in Ringer solution containing DCFDA at a final concentration of 10 µM. Erythrocytes were incubated at 37°C for 30 min in the dark and washed two times in Ringer solution. The DCFDA-loaded erythrocytes were resuspended in 200 µl Ringer solution and ROS-dependent fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD). Subsequently, the geomean of the DCFDA dependent fluorescence was determined.
Statistics
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis was made using ANOVA with Tukey's test as post-test and t test as appropriate. n denotes the number of different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments are differently susceptible to triggers of eryptosis, the same erythrocyte specimens have been used for control and experimental conditions.
Results
Effect of gefitinib on cell volume and cell membrane scrambling
The present study tested the effect of gefitinib on eryptosis, the suicidal erythrocyte death. Hallmarks of eryptosis include cell shrinkage and phospholipid scrambling of the cell membrane with phosphatidylserine translocation to the cell surface. As a measure of erythrocyte volume forward scatter was determined utilizing flow cytometry. The measurements were performed after incubation for 48 hours in Ringer solution without or with gefitinib (1 -3 µg/ml). As illustrated in Fig. 1B, a 48 hours exposure to gefitinib decreased the forward scatter, an effect reaching statistical significance at 2 µg/ ml gefitinib concentration.
Phosphatidylserine exposing erythrocytes were identified utilizing annexin-V-binding to phosphatidylserine, as determined by flow cytometry. Annexin-V-binding was analysed following an incubation of the erythrocytes for 48 hours in Ringer solution without or with gefitinib (1 -3 µg/ml). As shown in Fig. 2 , a 48 hours exposure to gefitinib increased the percentage of phosphatidylserine exposing erythrocytes, an effect again reaching statistical significance at 2 µg/ml gefitinib concentration. ] i , Fluo3 fluorescence was determined. The erythrocytes were analyzed after a 48 hours incubation in Ringer solution without or with gefitinib (1 -3 µg/ml). As a result, the Fluo3 fluorescence was similar following exposure to 1 µg/ml gefitinib (18.41 ± 0.77 a.u., n = 17), 2 µg/ml gefitinib (17.53 ± 0.71 a.u., n = 17), and 3 µg/ml gefitinib (20.78 ± 1.24 a.u., n = 17) and following incubation in the absence of gefitinib (19.12 ± 0.71 a.u., n = 17).
Signaling in gefitinib induced cell membrane scrambling
An additional series of experiments was performed to test whether gefitinib-induced translocation of phosphatidylserine to the erythrocyte surface was dependent on entry of extracellular Ca
2+
. To this end erythrocytes were incubated for 48 hours in the absence or presence of 3 µg/ml gefitinib in the presence or nominal absence of extracellular Ca
. As illustrated in Fig. 3 , removal of extracellular Ca 2+ significantly blunted the effect of gefitinib on annexin-V-binding. On the other hand, gefitinib significantly increased the percentage of annexin-V-binding erythrocyte even in the absence of extracellular Ca
. Accordingly, the gefitinib-induced cell membrane scrambling was partially, but not fully, dependent on the presence of extracellular Ca 2+ . A further stimulator of eryptosis is oxidative stress. In order to test, whether gefitinib induces oxidative stress, reactive oxygen species (ROS) were quantified utilizing 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA). As shown in Fig. 4, a 48 hours exposure to gefitinib (3 µg/ml) increased the DCFDA fluorescence of erythrocytes. Thus gefitinib did induce oxidative stress.
Discussion
The present observations reveal that gefitinib triggers eryptosis, the suicidal death of erythrocytes characterized by cell shrinkage and by cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface.
The effect of gefitinib on cell volume may be due to activation of K + channels, K + exit, cell membrane hyperpolarization, Cl -exit and thus cellular loss of KCl with water [50] . , an observation pointing to the involvement of additional mechanisms contributing to gefitinib induced cell membrane scrambling. As a matter of fact, gefitinib treatment significantly enhanced the abundance of reactive oxygen species, a well known trigger of eryptosis [50] .
Phosphatidylserine exposing erythrocytes are recognized by phagocytosing cells, engulfed and thus rapidly cleared from circulating blood [50] . The clearance of eryptotic erythrocytes results in anemia as soon as the loss of erythrocytes surpasses the formation of new erythrocytes by erythropoiesis [50] . The gefitinib concentrations required for the stimulation of eryptosis are well in the range of concentrations (1 -2.2 µg/ml) encountered in the plasma of patients receiving 2 -3.5 mg gefitinib once weekly [130] . The stimulation of eryptosis may thus well explain the anemia following gefitinib treatment.
The physiological purpose of eryptosis is the timely clearance of defective erythrocytes from circulating blood prior to hemolysis [50] . Failure to enter eryptosis may thus allow defective erythrocytes to undergo hemolysis with release of hemoglobin which may pass the renal glomerular filter, precipitate in the acidic lumen of renal tubules, occlude nephrons and thus lead to renal failure [131] .
Stimulation of eryptosis may further compromise microcirculation [52, [132] [133] [134] [135] [136] by adherance of phosphatidylserine exposing erythrocytes to the vascular wall [137] , as well as stimulation of blood clotting and thrombosis by phosphatidylserine exposing erythrocytes [132, 138, 139] .
In conclusion, gefitinib triggers erythrocyte cell membrane scrambling, an effect in part due to Ca 2+ entry and oxidative stress. The effect could contribute to the development of anemia during gefitinib treatment of malignancy.
Al Mamun
Bhuyan et al.: Gefitinib-Induced Eryptosis Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
